ATE389404T1 - Kappa-opioid-rezeptor-liganden - Google Patents

Kappa-opioid-rezeptor-liganden

Info

Publication number: ATE389404T1
Authority: AT; Austria
Prior art keywords: kappa opioid; opioid receptor; receptor ligands; antagonists; kappa
Prior art date: 2001-01-08

Application number

AT02713374T

Other languages

English (en)

Inventor

F Carroll

James Thomas

S Mascarella

Original Assignee

Res Triangle Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-08

Filing date

2002-01-07

Publication date

2008-04-15

2002-01-07 Application filed by Res Triangle Inst filed Critical Res Triangle Inst

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE389404T1 publication Critical patent/ATE389404T1/de

Links

102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 4
108020001588 κ-opioid receptors Proteins 0.000 title abstract 4
239000003446 ligand Substances 0.000 title 1
206010013663 drug dependence Diseases 0.000 abstract 2
208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
208000003698 Heroin Dependence Diseases 0.000 abstract 1
APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 abstract 1
229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
201000006145 cocaine dependence Diseases 0.000 abstract 1
229960002069 diamorphine Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000159 protein binding assay Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Psychology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT02713374T 2001-01-08 2002-01-07 Kappa-opioid-rezeptor-liganden ATE389404T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/755,021 US6974824B2 (en)	2001-01-08	2001-01-08	Kappa opioid receptor ligands

Publications (1)

Publication Number	Publication Date
ATE389404T1 true ATE389404T1 (de)	2008-04-15

Family

ID=25037376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02713374T ATE389404T1 (de)	2001-01-08	2002-01-07	Kappa-opioid-rezeptor-liganden

Country Status (9)

Country	Link
US (1)	US6974824B2 (de)
EP (1)	EP1363630B1 (de)
JP (2)	JP4511115B2 (de)
AT (1)	ATE389404T1 (de)
AU (1)	AU2002245229B2 (de)
CA (1)	CA2433603C (de)
DE (1)	DE60225673T2 (de)
ES (1)	ES2300436T3 (de)
WO (1)	WO2002053533A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7189737B2 (en) *	1991-08-09	2007-03-13	Research Triangle Institute	Cocaine receptor binding ligands
US6034256A (en) *	1997-04-21	2000-03-07	G.D. Searle & Co.	Substituted benzopyran derivatives for the treatment of inflammation
US6538010B1 (en) *	2000-11-08	2003-03-25	Research Triangle Institute	Compounds and methods for promoting smoking cessation
US6974824B2 (en) *	2001-01-08	2005-12-13	Research Triangle Institute	Kappa opioid receptor ligands
US7381721B2 (en)	2003-03-17	2008-06-03	Adolor Corporation	Substituted piperidine compounds
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
US6992090B2 (en)	2003-06-16	2006-01-31	Adolor Corporation	Substituted piperidine compounds and methods of their use
WO2005015242A1 (en) *	2003-08-06	2005-02-17	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor kappa 1 (opkr1)
US7872023B2 (en) *	2005-02-17	2011-01-18	Research Triangle Institute	Kappa opioid receptor ligands
US7399762B2 (en) *	2005-04-25	2008-07-15	Research Triangle Institute	Opioid receptor agonist compounds and their use in treatment of pain
US7476679B2 (en) *	2005-07-26	2009-01-13	Research Triangle Institute	Octahydroisoquinoline compounds as opioid receptor modulators
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
US7538110B2 (en)	2005-10-27	2009-05-26	Adolor Corporation	Opioid antagonists
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
US20100222345A1 (en) *	2006-08-09	2010-09-02	Caroline Jean Diaz	Novel compounds as antagonists or inverse agonists for opioid receptors
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2009094260A1 (en)	2008-01-22	2009-07-30	Eli Lilly And Company	Kappa selective opioid receptor antagonist
US8048895B2 (en) *	2008-04-18	2011-11-01	Research Triangle Institute	Kappa opioid receptor ligands
CA2727573A1 (en) *	2008-06-25	2009-12-30	Pfizer Inc.	Diaryl compounds and uses thereof
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
JP2013517326A (ja) *	2010-01-19	2013-05-16	リサーチ・トライアングル・インスティチュート	κオピオイド受容体結合リガンド
EP2539706B1 (de) *	2010-02-24	2015-03-04	Research Triangle Institute	Arylpiperazin-opioid-rezeptor-antagonisten
EP2773352B1 (de) *	2011-12-09	2017-06-28	Research Triangle Institute	1-substituiertes 4-arylpiperazin als kappa-opioid-rezeptorantagonist
US12161622B2 (en)	2021-05-04	2024-12-10	Janssen Pharmaceuticals, Inc.	Compositions and methods for the treatment of depression
EP4489730B1 (de)	2022-03-07	2026-01-21	Janssen Pharmaceuticals, Inc.	Zusammensetzungen mit atikaprant
CN119156211A (zh)	2022-03-07	2024-12-17	杨森制药公司	用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5767131A (en) *	1993-04-05	1998-06-16	Synaptic Pharmaceutical Corporation	Dihydropyridines and new uses thereof
US6268369B1 (en) *	1994-11-16	2001-07-31	Synaptic Pharmaceutical Corporation	5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6159990A (en) *	1997-06-18	2000-12-12	Synaptic Pharmaceutical Corporation	Oxazolidinones as α1A receptor antagonists
EP1512683B1 (de) *	1998-03-10	2011-08-31	Research Triangle Institute	Neue Opiate, Herstellungsverfahren und Verwendungen
HN1999000149A (es)	1998-09-09	2000-01-12	Pfizer Prod Inc	Derivados de 4,4-biarilpiperidina
US6218390B1 (en) *	1998-12-17	2001-04-17	Synaptic Pharmaceutical Corporation	Morpholinone and morpholine derivatives and uses thereof
EP1038872A1 (de)	1999-02-22	2000-09-27	Pfizer Products Inc.	4-Phenyl-4-heteroarylpiperdine Derivate als Opioid-Rezeptorligande
JP4340437B2 (ja) *	2000-10-31	2009-10-07	レンセラールポリテクニックインスティチュート	８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
US6974824B2 (en) *	2001-01-08	2005-12-13	Research Triangle Institute	Kappa opioid receptor ligands
WO2002055495A1 (en) *	2001-01-15	2002-07-18	Glaxo Group Limited	Aryl piperidine derivatives as inducers of ldl-receptor expression

2001
- 2001-01-08 US US09/755,021 patent/US6974824B2/en not_active Expired - Fee Related
2002
- 2002-01-07 DE DE60225673T patent/DE60225673T2/de not_active Expired - Lifetime
- 2002-01-07 CA CA2433603A patent/CA2433603C/en not_active Expired - Fee Related
- 2002-01-07 ES ES02713374T patent/ES2300436T3/es not_active Expired - Lifetime
- 2002-01-07 AT AT02713374T patent/ATE389404T1/de not_active IP Right Cessation
- 2002-01-07 WO PCT/US2002/000482 patent/WO2002053533A2/en not_active Ceased
- 2002-01-07 AU AU2002245229A patent/AU2002245229B2/en not_active Ceased
- 2002-01-07 JP JP2002554652A patent/JP4511115B2/ja not_active Expired - Fee Related
- 2002-01-07 EP EP02713374A patent/EP1363630B1/de not_active Expired - Lifetime
2009
- 2009-09-15 JP JP2009213451A patent/JP2009286807A/ja active Pending

Also Published As

Publication number	Publication date
WO2002053533A3 (en)	2002-09-19
US20020132828A1 (en)	2002-09-19
CA2433603A1 (en)	2002-07-11
ES2300436T3 (es)	2008-06-16
JP4511115B2 (ja)	2010-07-28
CA2433603C (en)	2011-03-22
JP2004521100A (ja)	2004-07-15
EP1363630A4 (de)	2006-05-24
JP2009286807A (ja)	2009-12-10
DE60225673T2 (de)	2009-04-23
EP1363630A2 (de)	2003-11-26
WO2002053533A2 (en)	2002-07-11
US6974824B2 (en)	2005-12-13
EP1363630B1 (de)	2008-03-19
AU2002245229B2 (en)	2006-03-16
DE60225673D1 (de)	2008-04-30

Legal Events

Date	Code	Title	Description
2008-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60225673D1 (de)	2008-04-30	Kappa-opioid-rezeptor-liganden
DE60233720D1 (de)	2009-10-29	Kappa-opioid-rezeptor-liganden
RU2455026C3 (ru)	2020-04-08	Антагонисты рецепторов для лечения метастатического рака
MA32892B1 (fr)	2011-12-01	Anticorps anti-cmet
IL189788A0 (en)	2008-08-07	Human monoclonal antibodies to cd70
BG108495A (en)	2004-08-31	5-ht receptor ligands and uses thereof
ATE266655T1 (de)	2004-05-15	Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
PL1957539T3 (pl)	2013-08-30	Ludzkie przeciwciała monoklonalne przeciwko białku kinazy tyrozynowej 7 (PTK7) i ich zastosowanie
MX2010005966A (es)	2010-06-15	Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
FR14C0075I2 (fr)	2015-05-22	Antagonistes des recepteurs muscariniques de l'acetylcholine
AP2006003566A0 (en)	2006-04-30	Muscarinic Acetycholine receptor antagonists.
EP1983002A3 (de)	2009-03-11	Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2007020502A3 (en)	2007-04-19	Cannabinoid receptor ligands and uses thereof
WO2009149485A3 (en)	2010-06-10	Compounds for treating amyloidoses
ZA200802641B (en)	2009-02-25	Human monoclonal antibodies to CD70
WO2008054597A3 (en)	2008-10-09	Tyrosine phosphorylation sites
DK1176963T3 (da)	2005-04-25	Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
EA200701853A1 (ru)	2008-08-29	Производные циклопентапиридина и тетрагидрохинолина
WO2008013934A8 (en)	2008-03-13	Tyrosine phosphorylation sites
EP1983003A3 (de)	2009-03-11	Tyrosinphosphorylationsstellen und spezifische Antikörper
ATE556071T1 (de)	2012-05-15	Kappa-opioidrezeptor-liganden
WO2002100350A3 (en)	2003-05-22	Dopamine receptor ligands and therapeutic methods based thereon
IL139217A0 (en)	2001-11-25	Monoclonal antibodies to the human ldl receptor, their production and use
DE60141896D1 (de)	2010-06-02	N,n'-diarylguanidine als il-8-rezeptor-antagonisten
WO2008036337A8 (en)	2008-07-03	Predicted phosphorylation sites